Eupraxia Pharmaceuticals (EPRX) Q2 2024 earnings summary

Executive summary

• Advanced clinical programs in eosinophilic esophagitis (EoE) and knee osteoarthritis (OA) with promising safety and efficacy data from ongoing studies.

• Presented positive Phase 2b and Phase 1b/2a results at major medical conferences, highlighting potential improvements over current therapies.

• Expanded the RESOLVE study for EoE based on strong interim results, increasing injection sites, participants, and follow-up duration.

• Listed common shares on Nasdaq, enhancing access to capital markets.

Financial highlights

• Reported net loss of $6.1 million for Q2 2024, down from $9.5 million in Q2 2023, mainly due to changes in fair value of matured financial instruments.

• Cash balance of $23.3 million as of June 30, 2024, up from $19.3 million at year-end 2023.

• 35,622,553 common shares issued and outstanding as of June 30, 2024.

Outlook and guidance

• Anticipates reporting new data from the fourth cohort of the RESOLVE study in the near term.

• Plans to engage with the FDA in Q4 2024 regarding the EP-104GI program and potentially expand U.S. trials.

• Management expects current cash resources to fund operations through Q2 2025.